Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular...
8
Transcript of Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular...
![Page 1: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal](https://reader034.fdocuments.net/reader034/viewer/2022042311/5ed8e3cf6714ca7f4768c296/html5/thumbnails/1.jpg)
![Page 2: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal](https://reader034.fdocuments.net/reader034/viewer/2022042311/5ed8e3cf6714ca7f4768c296/html5/thumbnails/2.jpg)
![Page 3: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal](https://reader034.fdocuments.net/reader034/viewer/2022042311/5ed8e3cf6714ca7f4768c296/html5/thumbnails/3.jpg)
![Page 4: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal](https://reader034.fdocuments.net/reader034/viewer/2022042311/5ed8e3cf6714ca7f4768c296/html5/thumbnails/4.jpg)
![Page 5: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal](https://reader034.fdocuments.net/reader034/viewer/2022042311/5ed8e3cf6714ca7f4768c296/html5/thumbnails/5.jpg)
![Page 6: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal](https://reader034.fdocuments.net/reader034/viewer/2022042311/5ed8e3cf6714ca7f4768c296/html5/thumbnails/6.jpg)
![Page 7: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal](https://reader034.fdocuments.net/reader034/viewer/2022042311/5ed8e3cf6714ca7f4768c296/html5/thumbnails/7.jpg)
![Page 8: Rev. DIABETES 61 Completa · Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N EnglJ Med 2015; 373:2117—28. Neal](https://reader034.fdocuments.net/reader034/viewer/2022042311/5ed8e3cf6714ca7f4768c296/html5/thumbnails/8.jpg)